Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 285 posts found.

AZ-BMS launch Onglyza in Europe

October 19, 2009
Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes

 Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …

News

Manufacturing facility news in brief

September 14, 2009
Manufacturing and Production BMS

Pharmafocus' round-up of manufacturing facility news includes plant disposals by BMS and Sanofi-Aventis, a new build for device company Haselmeier …

News

BMS profits surge ahead

July 30, 2009
Sales and Marketing BMS

Bristol Myers-Squibb's earnings growth massively outstripped its income in the second quarter of the year. The company saw its net …

News

BMS buys Medarex for $2.1 billion

July 24, 2009
Research and Development, Sales and Marketing BMS, MA, Medarex

Bristol-Myers Squibb is to spend $2.1 billion in buying Medarex, the human antibody drug discovery specialists. Princeton-based Medarex is best …

News

BMS launches cancer website

July 15, 2009
Medical Communications, Sales and Marketing BMS, Cancer, digi

Bristol-Myers Squibb has launched a new website for sufferers of chronic myeloid leukaemia (CML), a cancer of the blood. MyCMLCare.com …

News

Onglyza and Cimzia recommended by CHMP

July 2, 2009
Research and Development, Sales and Marketing AZ, BMS, EMEA, Europe, Ongylza

Bristol-Myers Squibb andAstraZeneca's type II diabetes treatment Onglyza is among the brands to have received positive opinions from the Committee …

News

BMS turns in solid first quarter results

May 1, 2009
Sales and Marketing BMS

Bristol-Myers Squibb turned in respectable figures for the first quarter of 2008, with net income up 5% to $921 million. …

News

Plavix sales help BMS into profit

January 29, 2009
Sales and Marketing BMS, Plavix

Strong fourth quarter sales of its blockbuster blood thinner Plavix have helped Bristol-Myers Squibb back into the black. Net earnings …

News

BMS denies further 10% staff cut

January 2, 2009
Sales and Marketing BMS, restructure

Bristol Myers Squibb has denied claims it is making a further 10% reduction to its work force, and said any …

News

BMS to cut extra 10% from workforce

December 17, 2008
Sales and Marketing BMS

Bristol-Myers Squibb is to cut its global workforce by an extra 10% before 2010, in order to reduce costs and …

News

BMS breast cancer drug rejected

November 27, 2008
Sales and Marketing BMS, Cancer, breast cancer

Bristol-Myers Squibb's breast cancer drug Ixempra has suffered a setback in the EU over safety concerns.The Committee for Medicinal Products …

News

Setback for Pfizer and BMS clotting drug

September 5, 2008
Sales and Marketing BMS, Pfizer, clot, cv

News

Roche maintains sales growth for Q3

November 2, 2007
Sales and Marketing BMS

Third quarter figures show Roche's top-selling products have all posted double-digit advances on the same period in 2006. Growth for …

News

BMS expands Indian biotech collaboration

March 21, 2007
Research and Development BMS, India

Bristol-Myers Squibb will establish a new integrated drug development facility in Bangalore as part of an expansion of its R&D …

News

New UK headquarters for Bristol-Myers Squibb

December 5, 2005
Sales and Marketing BMS, UK

Bristol-Myers Squibb UK has moved into a new state-of-the-art head office in Uxbridge.The £5.5 million building houses over 200 employees, …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023